Overall, based on the pro-tumorigenic effects of PARG activity, and the profound effect of PARG knockdown on tumor growth and metastasis, our data emphasize the potential of PARG inhibition as a rational approach to drugging the PAR pathway, beyond PARP1/2 inhibition, for anti-cancer therapy. The gene discussed is PARP1; the disease is cancer.